Beam Therapeutics Inc. (BEAM) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-06

Key Insights

Insider John M. Evans, CEO of Beam Therapeutics, has automatically sold 30,078 shares to cover tax withholding obligations upon the vesting of restricted stock units, suggesting a potential focus on managing his personal tax liabilities.
Evans also holds an indirect beneficial ownership of 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, indicating a long-term investment in the company.
The reported transactions were executed pursuant to a Rule 10b5-1 trading plan, providing a structured approach to insider trading that can help mitigate concerns around potential insider information.

Want the newest filings?

This analysis covers the filing from 2026-04-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-06

The reporting person, Amy Simon, who is the Chief Medical Officer of Beam Therapeutics Inc. (BEAM), sold 6,700 shares of common stock on April 1, 2026 at a price of $24.58 per share. This appears to be a routine transaction to cover tax withholding obligations upon the vesting of restricted stock units.
The reporting person holds a total of 102,735 shares of BEAM common stock, including 183 and 138 shares acquired through the company's employee stock purchase plan in 2025 and 2026, respectively.
The share sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating a pre-planned and non-discretionary nature of the transaction.

Filed: 2026-04-06

Bethany J. Cavanagh, the SVP of Finance and Treasurer at Beam Therapeutics Inc., has conducted an automatic sale of 3,242 shares of common stock on April 1, 2026 to cover tax withholding obligations upon the vesting of certain restricted stock units.
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Cavanagh on August 9, 2024, indicating a pre-planned transaction.
Cavanagh's remaining beneficial ownership of 51,171 shares represents her ongoing commitment and alignment with the company's long-term success.

Filed: 2026-04-06

The reporting person, Christine Bellon, who is the Chief Legal Officer of Beam Therapeutics Inc., sold 5,956 shares of the company's common stock on April 1, 2026 to cover tax withholding obligations upon the vesting of certain restricted stock units.
The sale of shares was part of a pre-arranged Rule 10b5-1 trading plan, indicating the transaction was non-discretionary and likely not a signal of the reporting person's sentiment about the company's prospects.
The number of shares beneficially owned by the reporting person following the transaction remains significant at 109,711 shares, suggesting they continue to have a substantial stake in the company.

Filed: 2026-04-06

Insider Giuseppe Ciaramella, the President of Beam Therapeutics, sold 11,810 shares of common stock on April 1, 2026 to cover tax withholding obligations on vested restricted stock units.
The sale was made pursuant to a previously adopted 10b5-1 trading plan, suggesting the transactions were pre-planned and not driven by discretionary trading.
Ciaramella still holds a significant position of 218,406 shares in Beam Therapeutics, indicating his continued commitment to the company.

Filed: 2026-04-02

Insider Giuseppe Ciaramella, President of Beam Therapeutics Inc., acquired 40,000 restricted stock units (RSUs) on 2026-03-31, which will vest in four equal installments over the next four years.
This RSU grant indicates Ciaramella's continued commitment and confidence in Beam Therapeutics' long-term growth and development.
The insider transaction provides a positive signal to investors about the company's prospects, as the President is willing to hold a significant equity stake.

Filed: 2026-04-02

Christine Bellon, the Chief Legal Officer of Beam Therapeutics, acquired 20,000 restricted stock units (RSUs) on 03/31/2026, demonstrating her commitment to the company.
Bellon's RSUs vest in four equal installments over the next four years, aligning her long-term incentives with the company's performance.
This insider transaction suggests Bellon's confidence in Beam Therapeutics' future prospects and her alignment with shareholder interests.

Filed: 2026-04-02

Bethany J. Cavanagh, the SVP of Finance and Treasurer at Beam Therapeutics Inc., has acquired 20,000 shares of the company's common stock through restricted stock units (RSUs).
This acquisition of shares aligns the interests of the reporting person with those of the company and its shareholders.
The reporting person's total beneficial ownership of Beam Therapeutics shares has increased to 54,813 following this transaction.

Filed: 2026-04-02

The Chief Medical Officer of Beam Therapeutics Inc. (BEAM) acquired 31,750 shares of the company's common stock through restricted stock units (RSUs) granted under the 2019 Equity Incentive Plan.
The RSUs vest in four equal installments on the first four anniversaries of the grant date, subject to the reporting person's continued service with the company.
This insider transaction suggests the Chief Medical Officer's confidence in the company's future and alignment with shareholder interests through equity-based compensation.

Filed: 2026-04-02

Sravan Kumar Emany, the Chief Financial Officer of Beam Therapeutics Inc. (BEAM), acquired 31,750 shares of the company's common stock through restricted stock units (RSUs) that vested on March 31, 2026.
The RSUs represent the contingent right to receive one share of BEAM's common stock, with the RSUs vesting in four equal installments on the first four anniversaries of the grant date.
This insider transaction suggests that the CFO has confidence in the company's long-term prospects and is aligning his interests with those of shareholders.

Filed: 2026-02-26

The reporting person, Giuseppe Ciaramella, who is the President of Beam Therapeutics Inc. (BEAM), exercised 35,000 stock options and immediately sold the same number of shares at a weighted average price of $32.0012, reflecting a profit of $15.0012 per share.
The reported transaction was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned sale of shares by the insider.
The insider still holds 190,216 shares of BEAM common stock after the reported transaction, suggesting they continue to maintain a significant ownership stake in the company.

Filed: 2026-01-26

Bethany J. Cavanagh, SVP of Finance and Treasurer, sold 6,198 shares of Beam Therapeutics Inc. (BEAM) at a weighted average price of $35.0005 pursuant to a 10b5-1 trading plan adopted in September 2025.
The insider sale represents a small portion (about 15%) of Cavanagh's total beneficial ownership of 34,813 shares in the company.
The transaction was conducted in a planned and systematic manner, which may indicate Cavanagh's confidence in the company's near-term performance and valuation.

Filed: 2026-01-26

Christine Bellon, the Chief Legal Officer, sold 1,371 shares of Beam Therapeutics Inc. (BEAM) on January 22, 2026, reducing her direct beneficial ownership to 95,667 shares.
The sale was executed pursuant to a Rule 10b5-1 trading plan that Bellon had adopted on September 16, 2025, suggesting pre-planned and regular insider transactions.
Insider selling can sometimes signal management's belief that the stock is overvalued or the company's prospects are less favorable, though the context of the planned sale should be considered.

Other reports for Beam Therapeutics Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.